Clinical Momentum Bounces Back... Biotech Stock Hits 52-Week Low Two Days Ago

Dyne Therapeutics Inc. (NASDAQ: DYN) closed at $19.35, up 7.56% from the previous day. Its market capitalization stands at roughly $3.2 billion (approximately ₩4.5 trillion), with a one-day increase of about $260 million (roughly ₩370 billion).

On June 3, the company announced the completion of subject enrollment in the registrational expansion cohort of its Phase 1/2 ACHIEVE trial of lead candidate DYNE-101 (zeleciment basivarsen) in patients with myotonic dystrophy type 1 (DM1). The stock had touched a 52-week low of $17.54 on June 2 and has since staged a technical rebound over two trading days.

Headquartered in Waltham, Massachusetts, Dyne Therapeutics is a clinical-stage biotech leveraging its FORCE platform to develop therapies for inherited neuromuscular disorders, including DYNE-101 for DM1 and DYNE-251 for Duchenne muscular dystrophy (DMD). Despite reporting a net loss of approximately $446 million for 2025, the company maintains about $1.1 billion in cash and short-term investments, providing sufficient runway for its near- and mid-term clinical programs.